| Literature DB >> 34580787 |
Agnieszka Daca1, Justyna Gołębiewska2, Marek Bronk3, Tomasz Jarzembowski4.
Abstract
The Gram negative rods as Escherichia coli and Klebsiella pneumoniae belong to the most common etiology agents of urinary tract infections. The aim of our study was to assess the diversity of biofilm formed in different urinary tract diseases and their impact on monocytes' adherence and activation. The bacteria were obtained from patients with different kidney problems. Some of the patients were after renal transplantation, some of them were not. Changes in the size and granularity of monocytes, as well as their adherence to biofilm, were assessed using FACSVerse flow cytometer after 1 h co-incubation of monocytes and bacterial biofilm in 37 °C. The obtained results were validated against monocytes incubated without bacteria. The isolates from patients with chronic kidney disease formed the most adherent biofilm regardless the presence or absence of inflammatory reaction. Adherence of monocytes also increased during therapy with immunosuppressive agents, but monocytes' response was different when cyclosporine or tacrolimus were used. Additionally the presence of inflammatory reaction in patients with kidney disease modified the monocytes response when the immunosuppressive drugs were used. Considering the obtained results, we conclude that the changes of monocytes' morphology in response to biofilm formed by Gram negative rods could become a tool to detect urinary tract infection, especially in those groups of patients, where the knowledge of ongoing inflammation is important and the standard tools fail to detect it.Entities:
Keywords: Adhesion; Biofilm; Immunosuppression; Kidney disease; Monocytes
Mesh:
Year: 2021 PMID: 34580787 PMCID: PMC8476471 DOI: 10.1007/s11274-021-03150-y
Source DB: PubMed Journal: World J Microbiol Biotechnol ISSN: 0959-3993 Impact factor: 3.312
Characteristic of patients
| No [W/M]* | Age [mean ± SD] | Immunosuppressive therapy | Underlying disease: no [W/M] | eGFR [mean ± SD] | Creatinine concentration | CRP | UTI presence | |
|---|---|---|---|---|---|---|---|---|
| All | 144 [97 / 47] | 50.72 ± 24.45 W 50.65 ± 25.51 M 50.87 ± 22.97 | Tacrolimus: 59 Cyclosporine: 4 Other: 15 None: 66 | ADPKD: 10 [8/2] | 36.90 ± 12.29 | 1.93 ± 0.94 | 87.32 ± 94.45 | 9/1 |
| Glomerulonephritis: 9 [3/6] | 46.00 ± 32.06 | 1.62 ± 0.79 | 34.60 ± 48.28 | 8/1 | ||||
| Nephropathy**: 10 [3/7] | 18.80 ± 6.88 | 2.89 ± 0.75 | 34.60 ± 48.28 | 7/3 | ||||
| Recurrent UTI: 8 [5/3] | 49.125 ± 30.27 | 1.67 ± 0.48 | 108.12 ± 150.22 | 5/3 | ||||
| SLE: 7 [7/0] | 38.28 ± 27.38 | 1.94 ± 0.70 | 11.07 ± 7.58 | 5/2 | ||||
| Nephrotic syndrome: 5 [3/2] | 25.66 ± 37.20 | 5.50 ± 0.00 | 26.58 ± 41.85 | 0/5 | ||||
| Chronic kidney disease#: 20 [18/2] | 34.88 ± 18.70 | 3.86 ± 7.51 | 41.15 ± 56.65 | 15/5 | ||||
| None: 11 [8/3] | 61.00 ± 36.32 | 1.34 ± 0.78 | 93.27 ± 85.78 | 9/2 | ||||
| Others: 64 [38/26] | 51.89 ± 34.62 | 2.31 ± 1.66 | 70.22 ± 98.32 | 42/22 | ||||
| RTx patients | 68 [44 / 24] | 51.09 ± 18.16 W 48.43 ± 20.20 M 55.96 ± 12.20 | Tacrolimus: 58 Cyclosporine: 4 Other: 6 None: 0 | ADPKD: 10 [8/2] | 36.90 ± 12.29 | 1.93 ± 0.94 | 87.32 ± 94.45 | 9/1 |
| Glomerulonephritis: 9 [3/6] | 46.00 ± 32.06 | 1.62 ± 0.79 | 34.60 ± 48.28 | 8/1 | ||||
| Nephropathy**: 0 [0/0] | – | – | – | – | ||||
| Recurrent UTI: 4 [2/2] | 33.00 ± 0.00 | 2.00 ± 0.00 | 2.30 ± 0.00 | 4/0 | ||||
| SLE: 5 [5/0] | 26.80 ± 12.35 | 2.21 ± 0.61 | 15.40 ± 5.40 | 3/2 | ||||
| Nephrotic syndrome: 0 [0/0] | – | – | – | – | ||||
| Chronic kidney disease#: 15 [13/2] | 28.86 ± 8.25 | 4.27 ± 7.95 | 36.37 ± 57.90 | 12/3 | ||||
| None: 0 [0/0] | – | – | – | – | ||||
| Others: 25 [13/12] | 41.62 ± 29.39 | 2.19 ± 1.46 | 72.85 ± 88.22 | 14/11 | ||||
| Non-RTx patients | 76 [49 / 27] | 50.39 ± 28.95 W 52.44 ± 28.21 M 45.37 ± 30.11 | Tacrolimus: 1 Cyclosporine: 0 Other: 9 None: 66 | ADPKD: 0 [0/0] | – | – | – | – |
| Glomerulonephritis: 0 [0/0] | – | – | – | – | ||||
| Nephropathy**: 10 [3/7] | 18.80 ± 6.88 | 2.89 ± 0.75 | 34.60 ± 48.28 | 7/3 | ||||
| Recurrent UTI: 4 [3/1] | 65.25 ± 36.23 | 1.005 ± 0.145 | 161.04 ± 59.53 | 1/3 | ||||
| SLE: 2 [2/0] | 67.00 ± 33.00 | 1.26 ± 0.36 | 2.40 ± 1.24 | 2/0 | ||||
| Nephrotic syndrome: 5 [3/2] | 25.66 ± 37.20 | 5.50 ± 0.00 | 26.58 ± 41.85 | 0/5 | ||||
| Chronic kidney disease#: 5 [5/0] | 63.00 ± 26.55 | 0.99 ± 0.31 | 72.20 ± 34.05 | 3/2 | ||||
| None: 11 [8/3] | 61.00 ± 36.32 | 1.34 ± 0.78 | 93.27 ± 85.78 | 9/2 | ||||
| Others: 39 [25/14] | 57.95 ± 36.02 | 2.41 ± 1.80 | 68.41 ± 104.67 | 28/11 |
*W—women, M—men
**Diabetic nephropathy and hypertensive nephropathy
***Y—yes, N—no, asymptomatic bacteriuria was not considered as UTI
#chronic kidney disease with unknown aetiology
Fig. 1Various features of patients impact the monocytes response to biofilm exposure in different manner. RTx recipient of kidney’s transplant, SSC side scatter (granularity of the cell)
Fig. 2Immunosuppressive therapy influences monocytes’ response to biofilm. ADH/K monocytes’ adherence to biofilm in plate’s well normalized to the monocytes’ adherence to the well’s bottom without biofilm
Fig. 3Monocytes’ response, measured as adherence to biofilm differs depending on the type of underlying disease. ADPKD autosomal dominant polycystic kidney disease; ADH/K monocytes’ adherence to biofilm in plate’s well, normalized to the monocytes’ adherence to the well’s bottom without biofilm
Fig. 4Monocytes’ response, measured as morphology changes, in response to biofilm depending on the type of immunosuppression and type of bacteriuria present. SSC/K granularity of monocytes exposed to biofilm normalized to the monocytes not exposed to biofilm. FSC/K the size of monocytes exposed to biofilm normalized to the monocytes not exposed to biofilm